Avopef

etoposide · ETOPOSIDE 500 mg/25mL · Injection · Intravenous · Avyxa Pharma, LLC

NDC 83831-0145-25 · 1 VIAL in 1 CARTON / 25 mL in 1 VIAL · NDA · View full market →

The short version

4 companies supply this market — a reasonable cushion if one runs into trouble.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

Part D specialty tier
Costs ≥ $950/fill · avg $41.77 per prescription
Biologic (BLA)
Injectable / infused
Orphan-drug exclusivity
REMS program

Regulatory

Application: NDA220200
TE code: —
Approval date: Feb 13, 2026
Patents / exclusivity: None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of etoposide (Injection)

Labeler	Strength	First seen	Last seen
Hikma Pharmaceuticals USA Inc.	ETOPOSIDE 20 mg/mL	Jul 15, 2026	Sep 3, 2026
Accord Healthcare Inc.	ETOPOSIDE 20 mg/mL	Jul 15, 2026	Sep 2, 2026
Avyxa Pharma, LLC	ETOPOSIDE 100 mg/5mL	Jul 15, 2026	Sep 2, 2026
Avyxa Pharma, LLC	ETOPOSIDE 500 mg/25mL	Jul 15, 2026	Sep 2, 2026
BluePoint Laboratories	ETOPOSIDE 20 mg/mL	Jul 15, 2026	Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Avopef — NDC 83831-0145-25," retrieved September 3, 2026, https://drugdashboards.com/drug/83831014525.

Free to cite with attribution — see how the data is put together.